CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, has completed an investment round of a total €13M.
Both existing and new investors participated in the round. The proceeds allow the company to begin multi-center clinical studies and complete its FDA approval process for the CathVision Cube system and associated software algorithms.